GSK supports the launch of “New Respiration and Frequent Care” online management platform for asthma patients in China

Supported by GSK, “New Respiration and Frequent Care” online management platform for patients with asthma in China (“the project”) was launched today in Guangzhou to improve the asthma control level. Organised by Guangzhou Institute of Respiratory Disease (GIRD) and State Key Laboratory of Respiratory Disease, the project aims to establish a standardised and nationwide asthma patient registry database to improve the diagnosis and treatment of asthma in China and patients’ self-management capabilities. 

The project is expected to last for three years. The first 12 months will cover 56 hospitals from eight regions, including Liaoning, Beijing, Sichuan, Chongqing, Hubei, Shanghai, Zhejiang and Guangdong. Tapping on the mobile and digital technologies, the project will establish a closed-loop asthma management system based on the asthma patient registry database comprising outpatients’ treatment and their self-management outside hospital. In this way, the project encourages closer communication between doctors and patients for an improved asthma control rate. 

Professor Nanshan Zhong, Director of the State Key Laboratory of Respiratory Diseases and Academician of the Chinese Academy of Engineering, said: "Improving the diagnosis and treatment for chronic respiratory diseases is one of our focuses during the period of 13th Five-Year Plan. By establishing a national online management platform for asthma patients, we hope to standardise the clinical diagnosis and treatment of asthma and improve the scientific research capabilities as well. The research outcome from the project will also provide reference for healthcare policies for the benefit of more Chinese patients."

The Third Epidemiological Study of Asthma in Children in Urban China showed that the cumulative prevalence of childhood asthma in China was 3.02%1. While the prevalence of asthma among people aged over 14 was 1.24%2, the overall control rate was just 28.7% in urban area3

Thomas Willemsen, General Manager, GSK China Pharmaceuticals and Vaccines, said: "The incidence of asthma is on the rise recently in the world and in China as well. GSK has extensive experience in the research on respiratory disease and real-world evidence globally. Through the cooperation with GIRD, we hope to enhance our collaboration with respiratory clinics and research institutions to improve the overall health capabilities and the patients’ self-management skills based on the real-world evidence."

GSK is committed to enhancing the healthcare capabilities in chronic airway diseases and helping Chinese patients to improve their condition and quality of life. In 2016, GSK partnered with China Association of Health Promotion and Education to support the establishment of "Asthma Clinic" in 20 hospitals in 4 provinces, having benefited more than 8,000 asthma patients as of today. In the near future, GSK is working on and committed to bringing more innovative and advanced medicines and solutions to provide individualised treatment for patients with chronic airway diseases in China.


As part of the ‘in China, with China, for China’ strategy, GSK China has:

  • Supported the launch of the UK-China Health and Economy Partnership in November 2017
  • Supported the launch of "Happy Breath", COPD Tiered Diagnosis and Treatment Project across China in November 2017.
  • Announced Flixotide Nebules received approval for the treatment of children asthma in September 2017.
  • Announced partnership with Ali Health to launch innovative online service platform to improve adult vaccination consultation experience in Aug 2017.
  • Announced innovative antiretroviral Single Tablet Regimen Triumeq received approval in China in Aug 2017.
  • Announced Cervarix, first vaccine for cervical cancer prevention in mainland China, was officially launched in July 2017.
  • Announced the collaboration programme to aid hepatitis prevention and treatment in poverty-stricken areas of the western region in July 2017.
  • Announced Seroxat CR and Tykerb on the list of reimbursed drugs as results of the national health insurance negotiations in July 2017.
  • Announced a strategic partnership with academia to co-develop health big-data system and upgrade the management of respiratory diseases in June 2017.
  • Aided the National Preventive Vaccination Services and Management Training Programme, helmed by the Chinese Preventive Medicine Association under the guidance of the National Health and Family Planning Commission, with the support of the China Centre for Disease Control and Prevention that officially kicked off in June 2017.
  • Announced Viread, Arixtra, Requip and Mivacron included in the “2017 National Reimbursement Drug List” in Mar 2017.
  • Joined hands with the Home of Red Ribbon to combat HIV/AIDS, unveiling plan to support people living with HIV in Nov 2016.
  • Announced the strategic partnership with China Preventive Medicine Association (CPMA) to address major public health challenges in China in Nov 2016.
  • Announced the approval of Cervarix in China to help protect women from cervical cancer in July 2016.
  • Announced a Memorandum of Understanding between the GSK Institute for Infectious Diseases and Public Health and Tsinghua University to tackle global public health challenges in June 2016.
  • Launched Tivicay, an innovative HIV drug, in June 2016.
  • Participated in the national price negotiation pilot and announced a price reduction of our first line chronic hepatitis B treatment, Viread, by up to 67% in May 2016.
  • Announced a Beijing-based Institute for Infectious Disease and Public Health to conduct local development programmes for pivotal HIV and TB R&D assets in March 2016.
  • Partnered with the National Health and Family Planning Commission on a multi-year programme to fund independent training programmes in Hepatitis and COPD for over 13,000 healthcare professionals from September 2015.
  • Transformed our commercial operating model to actively contribute to improving the quality of scientific exchanges with healthcare professionals for the benefit of patients since May 2015.


GSK – a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit


GSK commitment to China

We are a science-led global healthcare company. We research, develop and manufacture a wide range of medicines, vaccines and consumer healthcare products. People are at the heart of what we do. We strive to bring high quality, high performing products to everyone who needs them. Creating innovative products and improving access to them is critical to our mission, allowing us to help build stronger, healthier communities. In China, and around the world, we are on a mission to help people do more, feel better, live longer. We are in China, with China, for China, and our commitment remains unwavering.


GSK enquiries:

Susan Song            (China)



1. National Pediatric Asthma Coordination Group. The Third Epidemiological Study of Asthma in Children in Urban China. Chinese Journal of Pediatrics 2013: 51; 729-736

2. Nong Ying, Lin Jiangtao, Chen Ping, et al. Chinese Internal Medicine. 2017: 56; 485-489

3. Su Nan, Yuan Yadong, Zhou Xin, et al. The Sixth National Symposium on Asthma and 2nd conference of Chinese Association of Asthma 185-186


Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2016.